×

We source, finance and develop innovative assets and technologies across healthcare and life science sectors in selected EU markets




We have privileged relationships with leading universities/knowledge centers and pharma BD groups in Europe, providing direct access to innovative new technologies.

We recognize the value of industry guidance and have strategic relationships with a selected number of Industry Partners.

We will launch a dedicated investment fund called the Factory Fund, to exclusively invest in the best innovative science to build our portfolio.

We put our venture creation experience at work to translate and de-risk scientific innovation to ensure our portfolio flourishes and maximizing value for investors and interest to our Industry Partners.

Nico Vandervelpen

Nico Vandervelpen MSc

Managing Partner

Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.

Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope. Nico was nominated for the 2018 Bloomberg50 list.

Nico holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.

nico@bioqubeventures.com

Debora Dumont

Debora Dumont PhD

Managing Partner

Debora previously served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions including XO1 (acquired by Johnson & Johnson), FFPharma, Complix and Therasolve. Prior to joining LRM, between 2007 and 2010, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (now LifeTechValley).

Debora has a PhD in Biomedical Sciences from Hasselt University and holds a Masters degree in Bioscience Engineering from K.U. Leuven. Deborah is director at the Limburg Cancer Foundation.

debbie@bioqubeventures.com

Dirk Reyn

Dirk Reyn Ph MBA

Managing Partner

Dirk has gained deep commercial experience for more than 25 years at 2 leading pharma companies Eli Lilly and Janssen-Cilag (Johnson & Johnson). He was responsible for the launches and international strategic marketing of different products including Prozac (US/Belgium), Pariet (global) and Prepulsid (global). He was selected for streamlining JNJ’s e-business and became VP for new business development in Europe. In 2006, Dirk co-founded Movetis NV, a JNJ spin-off for GI assets. As CEO, he was instrumental in raising more than EUR €200 million over four years. Movetis had Resolor (prokinetic) approved in 2009 for chronic constipation and launched in four countries with reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Dirk worked two years for Shire as Managing director for the GI business in Europe.

In 2012 he founded Progress Pharma, an asset development company, with a team of experienced managers. With this team he supported Lipid Therapeutics in a deal with Nestle and co-founded eTheRNA, a spin-off from the University of Brussels with a breakthrough mRNA based immunotherapy for cancer & infectious diseases. In 2018, he worked with the founders as interim CEO of Spectricity, a spin-off from imec. He is board member of Spectricity, chairman of Flanders.bio, the organization of > 300 Flemish biotech companies and Chairman of Across Health, a global health CRM company.

Dirk Reyn is a Pharmacist and has an MBA from Handelshogeschool (Antwerpen)/Northwestern University (Kellog’s Chicago/USA).

dirk@bioqubeventures.com

Tol Trimborn

Tol Trimborn PhD

Venture Partner

Tol has over 15 years of experience in the life sciences and venture capital industry. He is a highly motivated, creative and dynamic entrepreneur. Tol serves and has served in a variety of management capacities, including CEO of Arcarios, COO of Gadeta, founder and general manager at DNage (acquired by Pharming). He has co-founded several companies including Arcarios and Gadeta.

Tol started his career as a Postdoctoral fellow conducting scientific research at the prestigious Howard Hughes Medical Institute of Stanford, became a leader of the molecular biology activities at Kalobios, an early-stage biotech start-up in Mountain View and expanded his scientific network into a commercially oriented network as a biotech analyst at LSP, The Netherlands.

Tol has a PhD in Medical Biology at the Erasmus University Rotterdam, The Netherlands and holds Masters degrees in biology and chemistry from Leiden University, The Netherlands.

tol@bioqubeventures.com

Joris De Maeyer

Joris De Maeyer PhD

Associate

Joris has 15 years' experience in the pharma-biotech sector, shaping and directing innovative and collaborative R&D programs. As an independent advisor, Joris currently provides strategic R&D and funding advise to international biotech companies and acts as Director R&D at Facio Therapies. Previously, Joris had various roles of increasing responsibility in start-ups as well as in large international companies such as Johnson & Johnson, Movetis and Shire Pharmaceuticals, where in his most recent position he served as Director Discovery.

Joris holds a PhD in Medical Sciences from Ghent University and a Masters in Bioscience Engineering from the Catholic University of Leuven.

joris@bioqubeventures.com

Olivier Houben

Olivier Houben LLM

Legal Counsel

He is a partner of Value for Growth, an independent consulting group. Olivier assisted in the creation and development of start-ups, supported companies & organisations with strategy development and implementation and together with leading (investment) banks helped companies with their fund-raising. Main achievements include assisting with the legal aspects of the creation of the venture capital fund Vesalius Biocapital I & III, co-operating with leading (investment) banks on fund-raising and legal counsel for Selligent, a multinational company of Belgian origin that provides relationship marketing solutions.

Olivier holds a Master’s Degree in Law from University of Louvain & University of Antwerp, as well as Special Licence Tax Law from the University of Brussels.

olivier@bioqubeventures.com

Alexander Demoulin

Alexander Demoulin MSc

Business Analyst

Alexander recently graduated from the University of Warwick with a Masters degree in Medical Biotechnology and Business Management and holds a Bachelor Degree in Biomedical Sciences from Antwerp University.

alexander@bioqubeventures.com

Géry Dams

Géry Dams MSc

Operations Manager

Géry started his career at Janssen in 1990 as a scientist in the department of Bacteriology & Mycology.  In 1998, Géry joined Tibotec in the role of team-leader cellular biology. After Tibotec was acquired by Johnson and Johnson, Géry became Associate Director e-Biology, Associate Director Target Validation & Engagement and finally Associate Director hit-to-lead and lead optimization within different discovery capability organizations at Janssen. In October 2017, Géry’s hit-to-lead and Lead optimization team was acquired by Charles River labs.

Géry holds a Master in Biochemistry from Breda Technical University.

gery@bioqubeventures.com

Géry Dams

Eve Van Breda MA

Office Manager & Communication Officer

Eve has a Bachelor’s degree in Communication Management and attended Business School at the University of Greenwich. She holds a Master’s degree in Cultural Management from Antwerp University.

eve@bioqubeventures.com

Joris Vanderlocht

Joris Vanderlocht PhD

Immunology Expert

Joris has over 15 years of experience in academic research and is specialized in the fundamental and translational aspects of human immunology. He started his career as a postdoctoral fellow at the Maastricht University Medical Center developing cellular immunotherapy for cancer. Later he managed several diagnostic programs in the clinic, including kidney transplantation, autoimmunity, immune deficiencies and hematological malignancies. Joris currently provides strategic R&D advise to various biotech companies as an independent consultant.

Joris holds a PhD in Biomedical Sciences from Hasselt University and a Masters degree in Biochemistry from the Catholic University of Leuven. He completed his training as a Medical Immunologist at the Maastricht University Medical Center. During this medical training he performed residencies in transplantation immunology at the UCLA in Los Angeles and at the Fred Hutchinson Cancer research center in Seattle.

jorisvanderlocht@bioqubeventures.com

March 2016

Bioqube ventures launches specialist investment firm and announces collaboration with Johnson & Johnson Innovation, JLINX

... Article

April 2016

JLINX incubator Launch Event - Sparking Life Science Innovation

September 2016

The JLINX building based at the Janssen R&D campus in Beerse, Belgium is ready to welcome life sciences startups

November 2016

JLINX award granted to S-Biomedic and Biomillenia in "Pitch Your Microbes" competition in collaboration with Janssen Human Microbiome Institute

April 2017

JLINX celebrates first birthday Catalyst for innovations in healthcare receives European and Flemish support

... Article

April 2017

JLINX award granted to Genome Biologics in the Startup Challenge, Hannover

... Website

June 2017

JLINX award granted to Gallinée in "Pitch Your Microbes" competition in collaboration with Janssen Human Microbiome Institute

... Website

October 2017

JLINX features in The Pharma Frontier magazine

... Article

November 2017

Bioqube Ventures managing partner, Nico Vandervelpen named by Bloomberg as one of the top people to watch in 2018

... Article

February 2018

Genome Biologics joins the JLINX Community

... Website

March 2018

JLINX incubator transitions into the first JLABS in Europe, JLABS @ BE

March 2018

Bioqube Ventures kick starts fundraising for independent VC fund

Contact

General & Investor Enquiries:
info@bioqubeventures.com

Or meet us at these events:

Antwerp Office
Turnhoutseweg 30
2340 Beerse, Belgium